MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia

FMS-like tyrosine kinase 3 (FLT3) is a key driver of acute myeloid leukemia (AML). Several tyrosine kinase inhibitors (TKIs) targeting FLT3 have been evaluated clinically, but their effects are limited when used in monotherapy due to the emergence of drug-resistance. Thus, a better understanding of...

Descripción completa

Detalles Bibliográficos
Autores principales: Morales, María Luz, Arenas, Alicia, Ortiz-Ruiz, Alejandra, Leivas, Alejandra, Rapado, Inmaculada, Rodríguez-García, Alba, Castro, Nerea, Zagorac, Ivana, Quintela-Fandino, Miguel, Gómez-López, Gonzalo, Gallardo, Miguel, Ayala, Rosa, Linares, María, Martínez-López, Joaquín
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901485/
https://www.ncbi.nlm.nih.gov/pubmed/31819100
http://dx.doi.org/10.1038/s41598-019-54901-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901485/
https://www.ncbi.nlm.nih.gov/pubmed/31819100
http://dx.doi.org/10.1038/s41598-019-54901-9

Ejemplares similares